VOC Diagnostics utilizes a unique method of analyzing volatile organic compounds in blood plasma samples to detect ovarian cancer at an early stage with high sensitivity and specificity. This technology addresses the critical challenge of late-stage diagnosis in ovarian cancer, which significantly impacts treatment outcomes and survival rates.
Funding
$880K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ovarian cancer is often diagnosed at a late stage due to the lack of effective early detection methods, leading to poorer treatment outcomes and reduced survival rates. Current diagnostic approaches lack the sensitivity and specificity needed to identify the disease in its early stages.
Solution
VOC Diagnostics employs a novel method of analyzing volatile organic compounds (VOCs) in blood plasma samples, combined with deep learning algorithms, to detect ovarian cancer at an early stage. This technology offers a non-invasive approach to cancer detection, potentially enabling earlier intervention and improved patient outcomes. By identifying specific VOC patterns associated with ovarian cancer, the method aims to provide higher accuracy compared to existing diagnostic techniques. The company is currently collecting clinical evidence to obtain regulatory approval for the European market, with a targeted market introduction in 2026.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and research institutions focused on early cancer detection and improved patient care in the field of ovarian cancer.
Features
- VOC analysis of blood plasma samples for early cancer detection
- Deep learning algorithms to enhance the accuracy of VOC pattern recognition
- Non-invasive diagnostic approach
- High sensitivity and specificity compared to existing methods
- Clinical evidence collection for regulatory approval in Europe